Spruce Biosciences (SPRB) Receivables - Accured (2021 - 2022)
Spruce Biosciences (SPRB) posted quarterly Receivables - Accured of $100000.0 for Q3 2022, down 25.93% quarter-over-quarter from $135000.0 in Q2 2022.
Spruce Biosciences (SPRB) Receivables - Accured (2021 - 2022) Analysis & Trends
Spruce Biosciences (SPRB) has reported Receivables - Accured for 2 consecutive years, with $100000.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Receivables - Accured changed N/A year-over-year to $100000.0; the TTM figure through Sep 2022 stood at $100000.0 (changed N/A YoY), while the FY2021 annual figure was $100000.0, changed N/A from the prior year.
- Receivables - Accured slipped to $100000.0 in Q3 2022 per SPRB's latest filing, from $135000.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $135000.0 in Q2 2022 and bottomed at $100000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 100,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 135,000.00 |
| Jun 30, 2022 | 135,000.00 |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |